Summary: Using a highly sensitive enzyme immunoassay (EIA) System, we determined creatine kinase isozymes, namely creatine kinase-MB and creatine kinase-MM, in sera of patients suffering from primary hypothyroidism with concomitant signs of myocardial affections before and during treatment. After oral administration of Ζ,-thyroxine, the augmented mass concentrations of serum creatine kinase-MB and creatine kinase-MM, and the increased catalytic activity concentrations of serum total creatine kinase and creatine kinase-MB gradually decreased in inverse proportion to the increased concentrations of serum triiodothyronine (T 3 ) and thyroxine (T 4 ). By the 6th to 8th week after treatment, the elevated levels of serum total creatine kinase and creatine kinase-MB catalytic activity concentrations (assayed by a routine method) and serum creatine kinase-MM mass concentrations (assayed by EIA) declined to normal vahies, while serum T 3 , T 4 , and thyroid stimulating hormone attained normal values. Serum creatine kinase-MB mass concentrations (assayed by EIA), however, still remained at the higher level, without complete recovery from myocardial damage, s show by electrocardiogram (ECG).
Introduction
concentration of creatine kinase-MB and creatine kinase^MM during treatment of hypothyroidism, using a Creatine kinase plays an importantrole in energymetab-Wghly sensitiye enzyme immunoassay system wh ich olism in muscles. Three isozymes are recognized, and was ablp to detect lower semm levels of creatine ^^, these exhibit tissue-specificity in their mode of distribu-M (9> 10) . tfais confirme d that serum creatine kinasetion; the BB form is found in the brain, the MB form in MB levels st l rema i ned hj g h, even though serum conthe heart, and the MM form in the skeletal muscles (l, een trations of thyroid stimulating hormone and thyroid 2). Isozyme, creatine kinase-MB, is easily released from hormones, and the serum catalytic activity concentracardiac muscle after acute myocardial infarction (3) (4) (5) . tions of total crea tine kinase and creatine kinase-MB Hypothyroidism induces the elevation of serum creatine mea sured by the routine method were normalized. kinase, aspartate aminotransfer se and lactate dehydrogenase activity concentrations, accompanied by electrocardiographic changes and signs of distorted skeletal Materials and Methods muscle metabolism (6, 7) . Gradual recovery from these .
The subjeets for this study were 20 patients (aged from 4s to 67 changes occurs after thyroid hormone replacement ther-years) at our unive^ity hospital, with rclativcly scvere hypothy- thyroidism (8 cases) associated'vvith abnormal elevation of creatine kinase isozyme catalytic activity concentrations. These patients revealed high serum catalytic activity concentration of total creatine kinase and high serum mass concentration of creatine kinase-MB. In all these patients, abnormal ECG findings (bradycardia and ST changes) were noted, suggesting myocardial damage due to hypothyroidism, äs shown by cardiac muscle biopsy (11) . None of tihe patients showed evidence of other cardiac diseases. Serum samples were collected every 2 weeks for 8 weeks after the administration of L-thyroxine (up 50 g/day every 1.5 weeks). We were able to check ECGs in 18 of these 20 patients during the course of the treatment. Blood samples were taken from a cubital vein in the early morning after fasting, then centrifuged to obtain the sera, vvhich were stored at -40 °C until use.
For the determination of creatine kinase isozyme mass concentration, we used a highly sensitive enzyme immunoassay (EIA), developed by Kalo et al. (9) , which has the capacity to detect a lower concentration of creatine kinase isozymes than the minimal concentration detectable by a routine method. A routine method for the determination of creatine kinase-MB catalytic activity concentration was reported previously (12) . The principle of this method is the direct measurement of creatine kinase-B subunit at 37 °C by inhibiting M subunits with M subunit antibody. A method for total creatine kinase was reported by Szasz et al. (13) . Total creatine kinase catalytic activity concentration was measured at 37 °C, using the Technicon RA System (Technicon Instruments Corporation, New Vork, USA). Creatine kinase-MB catalytic activity concentration is within 9% of total creatine kinase activity. The normal ranges reported in these papers were confirmed in our laboratory, using 50-60 samples from healthy subjects.
Results
Changes öf serum creatine kinase-MB and creatine kinase-MM mass concentrations and total creatine kinase and creatine kinase-MB catalytic activity concentration were analysed during the treatment of hypothyroid patients.
The augmented mass concentrations of serum creatine kinase-MB and creatine kinase-MM assayed by EIA and the increased catalytic activity concentration of serum total creatine kinase and creatine kinase-MB assayed by a routine method decreased gradually in inverse proportion to the increase in serum tniodothyronine (T 3 ) and thyroxine (T 4 ) levels. By the 6th-8th week after treatment, serum catalytic activity concentrations of total creatine kinase and creatine kiiiäse-MB assayed by a routine method, and serum mass concentrations of creatine kinase-MM assayed by EIA reached normal values ( fig. 1 ), corresponding to the normalization of serum T 3 , T 4 , arid thyrotropin levels (tab. 1). However, at this point, serum mass concentrations of creatine kinase-MB assayed by EIA were very low compared with those of total creatine kinase; they were hard to detect by a rou-
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S 600- Tab. 2 Changes in serum concentrations of thyroid hormones, thyrotropin and creatine kinase isozymes and changes of ECO during the treatmeht of hypothyroid patients (case l and 2). tinc method, but could be measured by a highly sensitive method; they still remained high in 12 patients (flg. Ic). In these latter 12 patients, the myocardial damage shown in the ECGs had not improved (7 cases of chronic thyroiditis, 5 cases of idiopathic hypothyroidism). The representative case is shown in table 2 (case 1). In the other six patients (3 cases of chronic thyroiditis, 3 cases of idiopathic hypothyroidism) who were checked by ECGs, the ST changes in ECGs subsided when the serum levels of creatine kinase-MB (assayed by EIA, not by a routine method) reached normal values during the course of the treatment (the representative case is shown in tab. 2, case 2). High creatine kinase-MB mass concentrations assayed by EIA declined to normal levels by the 12-14th week after treatment, concomitantly with normalization of the ECG (data not shown). The changes in serum catalytic concentfations of aspartate aminotransferase and lactate dehydrogenase in these patients paralleled changes in the catalytic activity concentration of total creatine kinase and the mass concentration of creatine kinase-MM.
Discussion
Since the distribution of creatine kinase isozymes is tissue-specific, several investigators (l, 2) have analysed serum levels and tissue contents of creatine kinase-isozymes, in order to estimate tissue damage in hypothyroid patients. It has been reported that in hypothyroidism, the isozyme analysis of elevated creatine kinase levels shows primarily an MM pattern, although a trace MB fraction could be seen, suggesting that the source of the creatine kinase elevations was skeletal muscle (14) . Our study clarified the fact that changes in serum total creatine kinase and creatine kinase-MB catalytic activity concentration and serum creatine kinase-MM and creatine kinase-MB mass concentrations correlate reciprocally with serum levels of thyroid hormones. However, the serum level of creatine kinase-MB, measured by a highly sensitive method, were still high. This creatine kinase-MB may arise from heart muscle rather than skeletal muscle, because the serum mass concentration of creatine kinase-MM, which represented more than 90% of creatine kinase-isozymes, was normalized. The ECG changes persisted when serum levels of thyroid hormones had been normalized by thyroid hormone replacement therapy. The change in creatine kinase-MB rnass concentrations rnay be mainly due to heart tissue, while the change in creatifte ; kinase-MM mass concentrations is mainly due to leg muscle tissue. It can be speculated that since changes of creatine kinase-MM precede those of creatine kinase-MB, recovery proceeds more rapidly in skeletal muscle than in myocardium. In addition to acute myocarditis and cardiomyopäthy (15) , which cause reversible ECG changes and cardiac enzyme abnormalities in the absence of myocardial infarction, hypothyroid patients also frequently display reversible myocardial damage associated with elevated cardiac enzyme activities. In patients with hypothyroidism and irreversible ECG changes induced by irreversible chronic myocardial damage, the reversible cardiac en-; , zyme abnormality, such äs creatine kinase-MB, may be ; önly a usefiil marker for hypothyroid^-induced myocar-j dial damage. l]
Latner et al. (16) have confirmed that creatine kinase-{ MB isozyme concentrations in the serum of uraemic pa-;| tients, measured by chemiluminometric immunoassay, jj correlated with those determined by an electrophoretic · method. Eisenberg et al. (17) have also reported that the rates of decrease in creatine kinase-MB catalytic activity and mass concentration äfter attaining their peak values were comparable in plasma samples from patients with myocardial infarction. Therefore, there may be no difference in the decay of creatine kinase-MB catalytic activity and mass concentration, or in the different sübspecies of creatine kinase-MB molecules, so that the data shown in figure Ic cannot be interpreted ön this basis.
When serum levels of creatine kinase-MB (measured by a highly sensitive method (9, 18) in hypothyroid patients treated with thyroid hormones) still remain high, even though serum levels of thyroid hormones, routinely measured total creatine kinase and creatine kinase-MB catalytic activity concentrations and EIA-assayed ereatine kinase-MM mass concentrations have become normal, careful attention müst be paid to the cärdioVascülaf System of the patient.
